JZYY(SH:600750)2016-10-21 16:00Financial Performance - The company's operating revenue for the first nine months decreased by 42.06% year-on-year, amounting to CNY 1,091,436,015.25[9] - The net profit attributable to shareholders increased by 15.11% year-on-year, reaching CNY 255,499,117.24[9] - The net cash flow from operating activities increased by 34.06% year-on-year, totaling CNY 581,777,408.58[9] - The pharmaceutical segment's revenue declined by 8.89% year-on-year, with a total revenue of CNY 1,087,818,413.45[13] - The revenue from the non-prescription drug segment was CNY 920,204,708.77, with a year-on-year decrease of 4.27%[13] - The revenue from health products and others was CNY 167,613,704.68, showing a significant decline of 27.98% year-on-year[14] - The revenue from the liquor segment was CNY 1,200,784.97, with a substantial increase of 175.46% year-on-year[13] - Total operating revenue for Q3 2016 was CNY 220,793,904.94, a decrease of 61.0% compared to CNY 565,591,060.38 in Q3 2015[36] - Net profit for Q3 2016 was CNY 58,892,002.60, a decrease of 29.3% compared to CNY 83,231,412.38 in Q3 2015[38] - The company's operating revenue for Q3 2016 was ¥172,113,082.74, a decrease of 36.1% compared to ¥269,111,023.15 in Q3 2015[41] - The net profit for Q3 2016 was ¥69,068,243.03, down 3.4% from ¥71,524,468.26 in the same period last year[42] Assets and Liabilities - The total assets at the end of the reporting period increased by 6.25% compared to the end of the previous year, amounting to CNY 2,845,758,473.90[9] - The total current assets reached ¥1,547,946,070.93, up from ¥1,368,903,631.70 at the start of the year, indicating an increase of 13.1%[28] - The company's total assets as of September 30, 2016, were ¥2,845,758,473.90, compared to ¥2,678,297,588.68 at the beginning of the year, reflecting a growth of 6.3%[29] - The total liabilities increased to ¥355,717,204.39 from ¥323,736,373.65, marking a rise of 9.9%[30] - Total liabilities for Q3 2016 were CNY 175,415,305.55, up 47.2% from CNY 119,162,025.69 in Q3 2015[34] Cash Flow - Cash and cash equivalents at the end of the period amount to 786 million RMB, an increase of 535.63 million RMB, representing a growth of 213.94%[20] - Accounts receivable at the end of the period is 362.05 million RMB, a decrease of 372.38 million RMB, representing a decline of 50.70%[20] - Cash inflow from operating activities for the first nine months of 2016 was ¥1,892,456,966.69, a decrease of 17.2% from ¥2,286,936,646.16 in the same period last year[45] - The net cash flow from operating activities for the first nine months of 2016 was ¥547,115,839.95, an increase of 54.7% compared to ¥354,212,278.14 in the same period last year[48] - Total cash inflow from operating activities reached ¥1,574,539,239.02, up from ¥1,504,164,634.93, reflecting a growth of 4.7% year-over-year[48] - Cash outflow from operating activities totaled ¥1,027,423,399.07, a decrease of 10.6% from ¥1,149,952,356.79 in the previous year[48] - The net cash flow from investment activities was -¥30,363,289.94, an improvement from -¥63,460,069.07 in the same period last year[48] - The net cash flow from financing activities was -¥52,347,103.56, an improvement from -¥172,711,660.49 in the same period last year[49] Shareholder Information - Total number of shareholders at the end of the reporting period is 21,726[18] - Jiangxi Jiangzhong Pharmaceutical (Group) Co., Ltd. holds 129,081,660 shares, accounting for 43.03% of total shares[18] Future Commitments - The company has committed to a cash dividend distribution of no less than 20% of the net profit attributable to shareholders for the next three years, provided there are no major investment plans or cash expenditures[23] - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[40]